ArticleDiscover oncology2025
Tall cell carcinoma with reversed polarity: case report of a rare special type of breast cancer and review of the literature.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tall cell carcinoma of the breast with reversed polarity (TCCRP) is a rare and diagnostically challenging subtype of triple-negative invasive breast carcinoma. Herein, we report a case of a 60-year-old female presenting with a two-year history of a left breast mass that exhibited progressive enlargement. Histopathological examination of the excised tumor revealed distinctive morphological features, including expansive nests of neoplastic cells with sharply demarcated borders and a spectrum of architectural patterns encompassing solid, follicular, and papillary configurations. Notably, papillary structures contained delicate fibrovascular cores infiltrated by foamy macrophages. The tumor cells demonstrated characteristic tall columnar to cuboidal morphology with nuclei displaying reversed polarity (basal-to-luminal nuclear polarization). Immunophenotypic analysis revealed a triple-negative profile (ER -/PR -/HER2 -) with co-expression of CK5/6 and GATA-3, while P63 staining confirmed the absence of myoepithelial differentiation. Molecular characterization identified an IDH2 p.R172S hotspot mutation, further corroborating the diagnosis. This case underscores the importance of integrating histomorphological features, immunohistochemical profiles, and molecular biomarkers to distinguish TCCRP from other triple-negative breast carcinomas. Recognition of this indolent entity is critical for avoiding overtreatment and ensuring appropriate clinical management, given its favorable prognosis compared to conventional triple-negative breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.